Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline
| Autor: | Matthew Mumber, Vinai Gondi, Mark R. Gilbert, Terri S. Armstrong, Nofisat Ismaila, Mary Lovely, Andrew E. Sloan, Minesh P. Mehta, Timothy F. Cloughesy, Susan M. Chang, Evanthia Galanis, Tracy T. Batchelor, Erik P. Sulman, Christina Tsien |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Cancer Research
medicine.medical_specialty Consensus Biopsy medicine.medical_treatment MEDLINE 03 medical and health sciences 0302 clinical medicine Quality of life Temozolomide Humans Medicine Medical physics Antineoplastic Agents Alkylating Evidence-Based Medicine Performance status Brain Neoplasms business.industry Patient Selection Chemoradiotherapy Guideline Evidence-based medicine Dacarbazine Radiation therapy Treatment Outcome Oncology 030220 oncology & carcinogenesis Dose Fractionation Radiation Cranial Irradiation Glioblastoma business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 35:361-369 |
| ISSN: | 1527-7755 0732-183X |
| Popis: | Purpose The American Society for Radiation Oncology (ASTRO) produced an evidence-based guideline on radiation therapy for glioblastoma. Because of its relevance to the ASCO membership, ASCO reviewed the guideline and applied a set of procedures and policies used to critically examine guidelines developed by other organizations. Methods The ASTRO guideline on radiation therapy for glioblastoma was reviewed for developmental rigor by methodologists. An ASCO endorsement panel updated the literature search and reviewed the content and recommendations. Results The ASCO endorsement panel determined that the recommendations from the ASTRO guideline, published in 2016, are clear, thorough, and based on current scientific evidence. ASCO endorsed the ASTRO guideline on radiation therapy for glioblastoma and added qualifying statements. Recommendations Partial-brain fractionated radiotherapy with concurrent and adjuvant temozolomide is the standard of care after biopsy or resection of newly diagnosed glioblastoma in patients up to 70 years of age. Hypofractionated radiotherapy for elderly patients with fair to good performance status is appropriate. The addition of concurrent and adjuvant temozolomide to hypofractionated radiotherapy seems to be safe and efficacious without impairing quality of life for elderly patients with good performance status. Reasonable options for patients with poor performance status include hypofractionated radiotherapy alone, temozolomide alone, or best supportive care. Focal reirradiation represents an option for select patients with recurrent glioblastoma, although this is not supported by prospective randomized evidence. Additional information is available at www.asco.org/glioblastoma-radiotherapy-endorsement and www.asco.org/guidelineswiki . |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|